



June 20, 2017

Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will host an Analyst and Investor Day on Tuesday, June 27, 2017. The event is scheduled to take place from 8:00-11:00 AM Eastern Time in New York City.

The agenda will include a review of the Company's HIF programs as well as presentations by the following guest speakers:

- | Geoffrey A. Block, M.D., Director of Research, Denver Nephrology
- | Cormac Taylor B.Sc., Ph.D., Professor of Cellular Physiology, University College Dublin, School of Medicine

A live audio webcast of the event will be available on the Company's website at <http://ir.akebia.com/events.cfm>. To ensure a timely connection, users should register at least 15 minutes prior to the scheduled start. An archived replay will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia's lead product candidate, vadadustat, is an oral, investigational therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global Phase 3 program for vadadustat, which includes the PRO₂TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO₂VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at www.akebia.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170620005296/en/>

Akebia:

Theresa McNeely, 617-844-6113
SVP, Corporate Communications
and Investor Relations
tmcneely@akebia.com

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media